This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Translational Prostate Cancer
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Clinical Trials
From the Editor
Search Clinical Trials
Trials in Progress
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Oral EPI-7386
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2022
ASCO GU 2023
EAU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2019
ESMO 2019
Prostate Cancer
Kidney Cancer
Bladder Cancer
Testicular Cancer
ESMO 2019 Kidney Cancer
Viewing 21-37 of 37 articles
ESMO 2019: A First-in-Human Phase I/II Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced Renal Cell Carcinoma
ESMO 2019: Primary Efficacy Analysis from the SORCE trial (RE05): Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse
ESMO 2019: Tailored Immunotherapy Approach with Nivolumab for Advanced Renal Cell Carcinoma (TITAN-RCC)
ESMO 2019: Invited Discussant - Review of SORCE and TITAN-RCC
ESMO 2019: Invited Discussant: Review of ENTRATA for Renal Cell Carcinoma and TROPHY-U-01 for Metastatic Urothelial Cancer
ESMO 2019: Invited Discussant: Results from the SORCE Trial and Nivolumab in Advanced Renal Cell Carcinoma, the TITAN-RCC Trial
ESMO 2019: Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse, Results from the SORCE Trial
ESMO 2019: A Tailored ImmunoTherapy Approach with Nivolumab in advanced Renal Cell Carcinoma in the TITAN-RCC Trial
ESMO 2019: CB-839 with Everolimus vs. Placebo with Everolimus in Patients with Renal Cell Carcinoma, the ENTRATA Phase 2 Study
ESMO 2019: Tailored ImmunoTherapy Approach with Nivolumab in Advanced Renal Cell Carcinoma
ESMO 2019: Primary Efficacy Analysis Results from the SORCE Trial: Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse
ESMO 2019: The Effect of Telaglenastat with Everolimus on Progression Free Survival in Patients with Advanced Renal Cell Carcinoma - Results from the Phase 2 ENTRATA Study
Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma
ESMO 2019: Invited Discussant: The Search for New Treatment Strategies in Genitourinary Cancer, Discussion of the ENTRATA (RCC) and TROPHY-U-01 (mUC) Trials
ESMO 2019: ENTRATA: Randomized, Double-Blind, Phase 2 Study of Telaglenastat + Everolimus vs. Placebo + Everolimus in Patients with Advanced/Metastatic Renal Cell Carcinoma
New Data for BAVENCIO® (avelumab) for Advanced Cancers To Be Presented at ESMO 2019
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
